A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhalation Aerosol in patients with bronchial asthma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Aged 18 to 75 years inclusive, regardless of gender;
• According to the definition in the Chinese Guidelines for Prevention and Treatment of Bronchial Asthma (2020 Edition), subjects diagnosed with bronchial asthma, including those with an initial diagnosis of asthma, or those diagnosed with asthma during childhood or adolescence with stable condition who have not received long-term treatment but exhibit significantly more pronounced symptoms in adulthood and/or recently compared to the past;
• Pre-randomization, pulmonary function tests show 60% ≤ FEV1% predicted ≤ 85%;
• Any objective test result indicating variable airflow limitation conducted within 1 year prior to screening is positive, or the bronchodilator test during the screening period is positive, i.e., an increase in FEV1 ≥ 12% and an absolute increase in FEV1 ≥ 200 mL 15-30 minutes after inhaling 400 μg salbutamol (if the bronchodilator test result does not meet the positive threshold, a repeat bronchodilator test is allowed within 14 days after the test \[excluding the test day\]); or the bronchial provocation test is positive, i.e., a decrease in FEV1 ≥ 20% after inhaling a provocant (methacholine or histamine); or the average daily diurnal variability of peak expiratory flow (PEF) (calculated as the sum of daily PEF diurnal variability over 7 consecutive days divided by 7) \> 10%;
• Voluntarily sign the informed consent form.
Locations
Other Locations
China
The First Affiliated Hospital of Nanchang University
RECRUITING
Nanchang
Contact Information
Primary
Mengli Kan
kanmengli@paloaltopharma.com
86-15618775927
Backup
Chunping Lu
luchunping@paloaltopharma.com
86-15921612878
Time Frame
Start Date:2025-02-24
Estimated Completion Date:2026-03
Participants
Target number of participants:60
Treatments
Experimental: PA9159 60 μg
Fifteen subjects will be randomly assigned to receive 60 μg of PA9159 Metered-Dose Inhaler for 28 days. Subjects will be administered three vials of drug (Inhaler bottle A ,Inhaler bottle B and Inhaler bottle C) Twice a day: In the morning, take 2 puffs from Bottle A and 2 puffs from Bottle B. In the evening, take 4 puffs from Bottle C.
Experimental: PA9159 120 μg
Fifteen subjects will be randomly assigned to receive 120 μg of PA9159 Metered-Dose Inhaler for 28 days. Subjects will be administered three vials of drug (Inhaler bottle A ,Inhaler bottle B and Inhaler bottle C) Twice a day: In the morning, take 2 puffs from Bottle A and 2 puffs from Bottle B. In the evening, take 4 puffs from Bottle C.
Experimental: PA9159 240 μg
Fifteen subjects will be randomly assigned to receive 240 μg of PA9159 Metered-Dose Inhaler for 28 days. Subjects will be administered three vials of drug (Inhaler bottle A ,Inhaler bottle B and Inhaler bottle C) Twice a day: In the morning, take 2 puffs from Bottle A and 2 puffs from Bottle B. In the evening, take 4 puffs from Bottle C.
Placebo_comparator: placebo
Fifteen subjects will be randomly assigned to receive placebo Metered-Dose Inhaler for 28 days. Subjects will be administered three vials of drug (Inhaler bottle A ,Inhaler bottle B and Inhaler bottle C) Twice a day: In the morning, take 2 puffs from Bottle A and 2 puffs from Bottle B. In the evening, take 4 puffs from Bottle C.